Cdk5 phosphorylates non-genotoxically overexpressed p53 following inhibition of PP2A to induce cell cycle arrest/apoptosis and inhibits tumor progression

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Ajay, Amrendra K ^a   Upadhyay, Ankur K ^a,b   Singh, Sandeep ^a,c   Vijayakumar, Maleppillil V ^a   Kumari, Ratna ^a   Pandey, Vimal ^a   Boppana, Ramanamurthy ^a   Bhat, Manoj K ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

^b Ranbaxy Research Laboratory   (India)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 5; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN BAX; PROTEIN P21; PROTEIN P53; SERINE; CDK5 PROTEIN, HUMAN; PHOSPHOPROTEIN PHOSPHATASE 2;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DNA FLANKING REGION; GENE ACTIVATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; HELA CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MITOCHONDRION; PROMOTER REGION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION; TUMOR GROWTH; TUMOR REGRESSION; UPREGULATION; CELL CYCLE; DRUG ANTAGONISM; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

HUMAN PAPILLOMAVIRUS;

APOPTOSIS; CELL CYCLE; CYCLIN-DEPENDENT KINASE 5; HUMANS; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77955059069     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-204     Document Type: Article

References (43)

1. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, vanTuinen P, Ledbetter DH, Barker DF, Nakamura Y, White R, Vogelstein B. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989, 244:217-221. 10.1126/science.2649981, 2649981.
2. Brown JC, Lain S, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nature Rev Cancer 2009, 9:862-873.
3. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991, 253:49-53. 10.1126/science.1905840, 1905840.
4. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990, 248:76-79. 10.1126/science.2157286, 2157286.
5. Camus S, Menendez S, Cheok CF, Stevenson LF, Lain S, Lane DP. Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6. Oncogene 2007, 26:4059-4070. 10.1038/sj.onc.1210188, 2742713, 17224909.
6. Thomas MC, Chiang CM. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol Cell 2005, 17:251-264. 10.1016/j.molcel.2004.12.016, 15664194.
7. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003, 22:5938-5945. 10.1038/sj.onc.1206894, 12955072.
8. Mantovani F, Banks L. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines. Oncogene 1999, 18:3309-3315. 10.1038/sj.onc.1202688, 10362351.
9. Yang C, Cirielli C, Capogrossi MC, Passaniti A. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 1995, 55:4210-4213.
10. Woodworth CD, Wang H, Simpson S, Alvarez-Salas LM, Notario V. Overexpression of wild-type p53 alters growth and differentiation of normal human keratinocytes but not human papillomavirus-expressing cell lines. Cell Growth Differ 1993, 4:367-376.
11. Hamada K, Alemany R, Zhang WW, Hittelman WN, Lotan R, Roth JA, Mitchell MF. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res 1996, 56:3047-3054.
12. St John LS, Sauter ER, Herlyn M, Litwin S, Adler-Storthz K. Endogenous p53 gene status predicts the response of human squamous cell carcinomas to wild-type p53. Cancer Gene Ther 2000, 7:749-756. 10.1038/sj.cgt.7700166, 10830722.
13. Burkhart BA, Alcorta DA, Chiao C, Isaacs JS, Barrett JC. Two posttranscriptional pathways that regulate p21 (Cip1/Waf1/Sdi1) are identified by HPV16-E6 interaction and correlate with life span and cellular senescence. Exp Cell Res 1999, 247:168-175. 10.1006/excr.1998.4345, 10047459.
14. Vogt M, Butz K, Dymalla S, Semzow J, Hoppe-Seyler F. Inhibition of Bax activity is crucial for the antiapoptotic function of the human papillomavirus E6 oncoprotein. Oncogene 2006, 25:4009-15. 10.1038/sj.onc.1209429, 16462759.
15. Gene therapy deserves a fresh chance. Nature editorial 2009, 461:1173.
16. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825. 10.1016/0092-8674(93)90500-P, 8242752.
17. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004, 303:1010-1014. 10.1126/science.1092734, 14963330.
18. Fang B, Roth JA. Tumor-suppressing gene therapy. Cancer Biol Ther 2003, 2:S115-121.
19. Nishizaki M, Fujiwara T, Tanida T, Hizuta A, Nishimori H, Tokino T, Nakamura Y, Bouvet M, Roth JA, Tanaka N. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. Clin Cancer Res 1999, 5:1015-1023.
20. McCormick F. Cancer-specific viruses and the development of ONYX-015. Cancer Biol Ther 2003, 2:S157-160.
21. Chhipa RR, Kumari R, Upadhyay AK, Bhat MK. Abrogation of p53 by its antisense in MCF-7 breast carcinoma cells increases cyclin D1 via activation of Akt and promotion of cell proliferation. Exp Cell Res 2007, 313:3945-3958. 10.1016/j.yexcr.2007.08.022, 17935714.
22. Upadhyay AK, Singh S, Chhipa RR, Vijayakumar MV, Ajay AK, Bhat MK. Methyl-beta-cyclodextrin enhances the susceptibility of human breast cancer cells to carboplatin and 5-fluorouracil: involvement of Akt, NF-kappaB and Bcl-2. Toxicol Appl Pharmacol 2006, 216:177-185. 10.1016/j.taap.2006.05.009, 16806341.
23. Zhao LY, Liao D. Sequestration of p53 in the cytoplasm by adenovirus type 12 E1B 55-kilodalton oncoprotein is required for inhibition of p53-mediated apoptosis. J Virol 2003, 77:13171-13181. 10.1128/JVI.77.24.13171-13181.2003, 296092, 14645574.
24. Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci USA 1999, 96:13777-13782. 10.1073/pnas.96.24.13777, 24141, 10570149.
25. Cohen P, Cohen PT. Protein phosphatases come of age. J Biol Chem 1989, 264:21435-21438.
26. Yan Y, Mumby MC. Distinct roles for PP1 and PP2A in phosphorylation of the retinoblastoma protein. PP2a regulates the activities of G(1) cyclin-dependent kinases. J Biol Chem 1999, 274:31917-31924. 10.1074/jbc.274.45.31917, 10542219.
27. Millward TA, Zolnierowicz S, Hemmings BA. Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci 1999, 24:186-191. 10.1016/S0968-0004(99)01375-4, 10322434.
28. Olsson A, Manzl C, Strasser A, Villunger A. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression?. Cell Death Differ 2007, 14:1561-1575. 10.1038/sj.cdd.4402196, 17627286.
29. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007, 8:275-283. 10.1038/nrm2147, 17380161.
30. Braun K, Ehemann V, Waldeck W, Pipkorn R, Corban-Wilhelm H, Jenne J, Gissmann L, Debus J. HPV18 E6 and E7 genes affect cell cycle, pRB and p53 of cervical tumor cells and represent prominent candidates for intervention by use peptide nucleic acids (PNAs). Cancer Lett 2004, 209:37-49. 10.1016/j.canlet.2004.02.022, 15145519.
31. Buxbaum JD, Dudai Y. A quantitative model for the kinetics of cAMP-dependent protein kinase (type II) activity. Long-term activation of the kinase and its possible relevance to learning and memory. J Biol Chem 1989, 264:9344-9351.
32. Lu J, Kovach JS, Johnson F, Chiang J, Hodes R, Lonser R, Zhuang Z. Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc Natl Acad Sci USA 2009, 106:11697-11702. 10.1073/pnas.0905930106, 2710674, 19564615.
33. Hengstermann A, Linares LK, Ciechanover A, Whitaker NJ, Scheffner M. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci USA 2001, 98:1218-1223. 10.1073/pnas.031470698, 14735, 11158620.
34. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004, 116:205-219. 10.1016/S0092-8674(04)00046-7, 14744432.
35. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004, 4:793-805. 10.1038/nrc1455, 15510160.
36. Xiong Y, Zhang H, Beach D. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 1992, 71:505-514. 10.1016/0092-8674(92)90518-H, 1358458.
37. Lee JH, Kim HS, Lee SJ, Kim KT. Stabilization and activation of p53 induced by Cdk5 contributes to neuronal cell death. J Cell Sci 2007, 120:2259-2271. 10.1242/jcs.03468, 17591690.
38. Goodyear S, Sharma MC. Roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein cdk5. Exp Mol Pathol 2007, 82:25-32. 10.1016/j.yexmp.2006.09.002, 17081516.
39. Strock CJ, Park JI, Nakakura EK, Bova GS, Isaacs JT, Ball DW, Nelkin BD. Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res 2006, 66:7509-7515. 10.1158/0008-5472.CAN-05-3048, 16885348.
40. Upadhyay AK, Ajay AK, Singh S, Bhat MK. Cell cycle regulatory protein 5 (Cdk5) is a novel downstream target of ERK in carboplatin induced death of breast cancer cells. Curr Cancer Drug Targets 2008, 8:741-752. 10.2174/156800908786733405, 19075597.
41. Tsai LH, Delalle I, Caviness VS, Chae T, Harlow E. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 1994, 371:419-423. 10.1038/371419a0, 8090221.
42. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, Gostissa M, Coen S, Marchetti A, Del Sal G, Piaggio G, Fanciulli M, Appella E, Soddu S. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 2002, 4:11-19. 10.1038/ncb714, 11780126.
43. Moroni MC, Hickman ES, Lazzerini Denchi E, Caprara G, Colli E, Cecconi F, Müller H, Helin K. Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol 2001, 3:552-558. 10.1038/35078527, 11389439.